Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received a consensus rating of "Buy" from the nine ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $39.86.
ORKA has been the subject of several recent analyst reports. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wolfe Research assumed coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock.
Check Out Our Latest Stock Analysis on ORKA
Oruka Therapeutics Price Performance
Shares of NASDAQ:ORKA traded up $0.08 during trading on Friday, reaching $11.26. The stock had a trading volume of 25,261 shares, compared to its average volume of 294,372. The stock has a 50-day moving average of $16.34. Oruka Therapeutics has a one year low of $10.61 and a one year high of $53.88. The firm has a market cap of $393.93 million, a P/E ratio of -1.80 and a beta of 0.77.
Hedge Funds Weigh In On Oruka Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics in the third quarter valued at about $1,037,000. FMR LLC acquired a new position in Oruka Therapeutics in the 3rd quarter worth approximately $114,763,000. Great Point Partners LLC purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $12,614,000. Braidwell LP acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at approximately $12,640,000. Finally, Janus Henderson Group PLC acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at approximately $5,840,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free ReportOruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
